Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

por Dudek, A Z, Lesniewski-Kmak, K, Shehadeh, N J, Pandey, O N, Franklin, M, Kratzke, R A, Greeno, E W, Kumar, P
Publicado 2009

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

por Khatri, A, Williams, B W, Fisher, J, Brundage, R C, Gurvich, V J, Lis, L G, Skubitz, K M, Dudek, A Z, Greeno, E W, Kratzke, R A, Lamba, J K, Kirstein, M N
Publicado 2014